Stocktoria
CRISPR Therapeutics AG CRSP
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-10-19
CRISPR Therapeutics AG financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| R&D expense | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M |
| Income tax | $3.6M | $3.6M | $2.9M | -$325,000 | $1.9M |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M |
| EPS (diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M |
| Cash & equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M |
| Total assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M |
| Shareholders' equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B |
Source: SEC EDGAR filings · CIK 0001674416 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.